Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a recombinant trivalent HPV vaccine (types 16/18/58) in Chinese women aged 18-45 years
CTR20201795Phase 3Active
- Sponsor
- Beijing Health Guard
- Start
- Oct 2020
- Countries
- 1
01
Overview
A Phase 3 trial of trivalent human papillomavirus recombinant vaccine in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma in situ (AIS), Cervical Cancer (CC), vulvar intraepithelial neoplasia (VIN), sponsored by Beijing Health Guard. Started Oct 2020; status: active.
02
Drugs
trivalent human papillomavirus recombinant vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)cervical adenocarcinoma in situ (AIS)Cervical Cancer (CC)vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on CTR20201795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201795.